证券代码:600789 证券简称:鲁抗医药 公告编号:2025-010 山东鲁抗医药股份有限公司 2024 年年度利润分配方案公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●本次利润分配以实施权益分派股权登记日登记的总股本为基数，具体日期将在 权益分派实施公告中明确。在实施权益分派的股权登记日前公司总股本发生变动的， 拟维持每股分配比例不变，相应调整分配总额，并将另行公告具体调整情况。 一、利润分配方案内容 （一）利润分配方案的具体内容 截止 2024 年 12 月 31 日，公司母公司报表中期末未分配利润为人民 币 310,614,159.98 元。经董事会决议，公司 2024 年年度拟以实施权益分 派股权登记日登记的总股本为基数分配利润。本次利润分配方案如下： 公司拟向全体股东每 10 股派发现金红利 1.12 元（含税）。截至 2024 年 12 月 31 日，公司总股本 898,669,632 股，以此计算合计拟派发现金红 利 100,650,998.784 元（含税）。 公司 2024 年半年 ...

Financial Performance - The company's operating revenue for 2024 reached CNY 6,233,090,168.38, representing a 1.41% increase compared to CNY 6,146,721,439.54 in 2023[23] - Net profit attributable to shareholders of the listed company was CNY 394,615,735.73, a significant increase of 60.30% from CNY 246,171,797.53 in the previous year[23] - The net assets attributable to shareholders of the listed company increased by 8.49% to CNY 3,918,185,214.35 from CNY 3,611,695,001.53 in 2023[24] - The total assets of the company rose by 3.36% to CNY 9,097,984,876.42 compared to CNY 8,802,431,497.87 in the previous year[24] - Basic earnings per share increased by 57.14% to CNY 0.44 in 2024 compared to CNY 0.28 in 2023[25] - The weighted average return on equity rose to 10.43%, an increase of 3.36 percentage points from 7.07% in 2023[25] - The company achieved a revenue of 6.233 billion RMB, representing a year-on-year growth of 1.41%[54] - The net profit attributable to shareholders reached 395 million RMB, marking a significant increase of 60.30% compared to the previous year[54] Dividend Distribution - The company plans to distribute a cash dividend of CNY 1.32 per 10 shares, totaling CNY 118,624,400 (including tax), which accounts for 30.06% of the net profit attributable to shareholders[7] - The cash dividend for the second half of 2024 is expected to be CNY 1.12 per 10 shares, with an estimated total distribution of CNY 100,651,000 (including tax)[7] - The total cash dividend amount for the last three fiscal years (including tax) is RMB 248,265,357.45, with an average annual net profit of RMB 259,600,220.88, resulting in a cash dividend payout ratio of 95.63%[173] Operational Efficiency - The net cash flow from operating activities decreased by 33.31% to CNY 402,818,057.13 from CNY 604,005,701.85 in 2023[24] - The company achieved a comprehensive energy consumption of 0.30 tons of standard coal per 10,000 yuan of output value, significantly reducing COD emissions from wastewater[36] - The company has implemented a transparent procurement system to improve efficiency and reduce operational costs[43] - The company reported a 5% reduction in operational costs due to efficiency improvements[146] Research and Development - R&D investment continued to grow rapidly, with 6 new raw material drug registration numbers and 10 generic drug approvals obtained[34] - The total R&D expenditure amounted to ¥401,566,973.69, representing 6.44% of the operating revenue[67] - The company is focusing on enhancing its R&D capabilities, with significant investments in innovative drugs, biomanufacturing, and high-end formulations[49] - The company has three innovative drugs in clinical trials, with two in Phase II and one in Phase I[101] - The company’s R&D investment totaled 402 million RMB, accounting for 6.44% of total operating revenue, which is relatively high compared to industry peers[110] Market Expansion and Product Development - The company is actively expanding its product lines in areas such as anti-infection, diabetes, and cardiovascular drugs, while also enriching its pipeline of specialty products[42] - The company is focusing on expanding its market presence and enhancing R&D capabilities to meet the growing demand for high-quality medical services[77] - The company is actively pursuing consistency evaluations for its generic drugs[103] - The company is focusing on areas such as anti-infectives, cardiovascular, respiratory, neurodegenerative diseases, metabolism, and oncology[101] Environmental Responsibility - The company invested RMB 18,120.29 million in environmental protection during the reporting period[180] - The wastewater from the company's subsidiaries meets the discharge standards, with COD and ammonia nitrogen concentrations consistently below regulatory limits[184] - The company has implemented carbon reduction measures, successfully reducing carbon dioxide equivalent emissions by 57,444 tons through projects like energy-efficient motor upgrades and solar power generation[195] - The company reported zero administrative penalties due to environmental issues during the reporting period[191] Corporate Governance - The company strictly adheres to information disclosure regulations, ensuring fairness and transparency in its communications with investors[136] - The company has established a comprehensive internal control system that meets the requirements of relevant regulatory bodies, ensuring effective operation and risk prevention[177] - The company has implemented a performance evaluation method for senior management to assess their operational performance[150] - The company held its annual shareholder meeting on April 23, 2024, where 14 proposals were approved without any rejections[137] Strategic Outlook - Future outlook includes plans for market expansion and potential mergers and acquisitions to strengthen the company's position in the pharmaceutical industry[144] - The company has set ambitious performance guidance for the upcoming fiscal year, projecting a revenue growth rate of over 15%[144] - The company plans to enter two new international markets, which could potentially increase overall sales by 20%[145] - The company is considering strategic acquisitions to enhance its product portfolio, targeting a completion by the end of 2024[148]

证券代码：600789 证券简称：鲁抗医药 公告编号：2025-007 山东鲁抗医药股份有限公司 关于控股子公司获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，山东鲁抗医药股份有限公司（以下简称"公司"）控股子公司山东鲁 抗医药集团赛特有限责任公司（以下简称"赛特公司"）收到国家药品监督管理 局颁发的关于利格列汀片（以下简称"该药品"）的《药品注册证书》（批件号： 2025S00320），该药品是按照新注册分类 4 类获批的仿制药，视为通过仿制药质 量和疗效一致性评价。现将相关情况公告如下： 一、药品证书基本信息 药品名称： 利格列汀片 注册分类：化学药品 4 类 生产企业：山东鲁抗医药集团赛特有限责任公司 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注册证书。质量标准、说明书、 标签及生产工艺照所附执行。药品生产企业应当符合药品生产质量管理规范要求 方可生产销售。 二、药品研发及市场情况 利格列汀是二肽基肽酶 4（DPP-4）抑制 ...

Core Viewpoint - Lu Kang Pharmaceutical (600789) is expected to achieve a net profit of 350 million to 415 million yuan in 2024, representing a year-on-year increase of 42% to 69% [1] Group 1: Financial Performance - The company anticipates significant growth in sales revenue from its main products compared to the previous year [1] - The expected pre-tax income from land reserve is projected to be 156 million yuan following the completion of land transfer procedures for the southern plant [1]

Financial Performance Forecast - The company expects a net profit attributable to shareholders of the parent company for 2024 to be between 350 million and 415 million CNY, representing a year-on-year increase of 42% to 69%[2] - The projected net profit attributable to shareholders of the parent company, excluding non-recurring gains and losses, is estimated to be between 192 million and 225 million CNY, reflecting a year-on-year increase of 10% to 29%[3] - The previous year's net profit attributable to shareholders of the parent company was 246.17 million CNY, with a total profit of 272.98 million CNY[4] Revenue Growth - The company has achieved significant growth in sales revenue of its leading products due to ongoing performance management and product technology upgrades[5] - The company has received approval for 32 new generic drug registrations since 2021, contributing to rapid revenue growth from new products[5] Land Compensation - The land compensation amount from the transfer of the southern plant area is estimated to be 337.57 million CNY, with a pre-tax gain from land storage expected to be 155.84 million CNY after deducting related expenses[5] Performance Forecast Accuracy - The company emphasizes that there are no significant uncertainties affecting the accuracy of this performance forecast[6] - The forecast data is preliminary and subject to final audited financial results in the 2024 annual report[7]

法律意见书 二〇二五年一月 中国北京市建国门外大街 1 号国贸写字楼 2 座 12-15 层 100004 12-14th Floor, China World Office 2, No.1 Jianguomenwai Avenue, Beijing 100004, China 电话 Tel: +86 10 6563 7181 传真 Fax: +86 10 6569 3838 电邮 Email: beijing@tongshang.com 网址 Web: www.tongshang.com 北京市通商律师事务所 北京市通商律师事务所 关于山东鲁抗医药股份有限公司 2025 年第一次临时股东大会的 关于山东鲁抗医药股份有限公司 2025 年第一次临时股东大会的法律意见书 致：山东鲁抗医药股份有限公司 根据《中华人民共和国律师法》《中华人民共和国公司法》（以下简称"《公司法》"） 《中华人民共和国证券法》（以下简称"《证券法》"）《上市公司股东大会规则》（以 下简称"《股东大会规则》"）《上海证券交易所上市公司自律监管指引第 1 号——规 范运作》（以下简称"《规范运作指引》"）等法律、法规和规范性文件以及《山东 ...

重要提示： ● 山东鲁抗医药股份有限公司（以下简称"公司"）股票于2025年1月9日、 2025年1月10日和1月13日连续3个交易日内收盘价格跌幅偏离值累计超过20%，根 据《上海证券交易所交易规则》的有关规定，属于股票交易异常波动情形。 ●经公司自查并向控股股东书面函证，除公司已披露的向特定对象发行 A 股股票外，截至本公告披露日，不存在应披露而未披露的重大信息。 一、股票交易异常波动的具体情况 2025年1月9日、1月10日和1月13日，公司股票连续3个交易日内收盘价格跌 幅偏离值累计超过20%。根据《上海证券交易所交易规则》的有关规定，属于股 票交易异常波动情形。 证券代码：600789 证券简称：鲁抗医药 公告编号：2025—003 山东鲁抗医药股份有限公司 股票交易异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 二、公司关注并核实的相关情况 （一）生产经营情况 经公司自查，公司目前生产经营活动正常，日常经营情况未发生重大变化， 市场环境、行业政策未发生重大调整，内部生产经营秩序正常。 公司所从事的主要 ...

Shandong Lukang Pharmaceutical Co.,Ltd. 山东鲁抗医药股份有限公司 6. 投票时请股东按次序将表决票投入表决箱内。 7. 宣读现场会议表决结果。 二、参加网络投票的股东需注意事项 2025 年第一次临时股东大会参会须知 根据《公司法》和《上市公司股东大会议事规则》的有关规定，为保证 公司股东依法行使股东权利，本次股东大会将采取现场会议和网络投票方式 表决，股东投票前请阅读本须知。 一、出席现场会议的股东需注意事项 1. 现场会议由公司董事会召集召开，由董事长主持。董事会有义务维 护股东合法权益，确保会议的正常秩序和议事效率。 2. 股东及股东代表请按时有序进入指定会场，到场签名。 3. 股东参加股东大会，依法享有发言权、表决权等权利，请认真履行 法定义务，自觉遵守大会秩序，不得侵犯其他股东的权益。 4. 大会警卫人员有权对不符合大会要求的入场人员进行处理。 5. 本次股东大会现场会议采取记名投票方式逐项进行表决，股东对非 累积投票议案按其所持有本公司的每一份股份享有一份表决权，特请各位股 东及其股东代表或其委托代理人准确填写表决票：必须填写股东姓名或委托 股东姓名，同意请 ...

财联社1月7日电，财联社星矿数据显示，今日早盘主力资金净流入电子、光学光电子、交运设备等板 块，净流出医药、非银金融、电新行业等板块，其中医药板块净流出超25亿元。 个股方面，利欧股份涨停，主力资金净买入4.63亿元位居首位，京东方A、山子高科、TCL科技获主力 资金净流入居前；鲁抗医药遭净卖出超6亿元，东方财富、宁德时代、中芯国际主力资金净流出额居 前。 ...